Gynecological cancers in patients with inflammatory rheumatic diseases

被引：0

作者：

Schmalzing, M. ^{[1
]}

Krockenberger, M. ^{[2
]}

Honig, A. ^{[3
]}

Tony, H. -P. ^{[1
]}

机构：

[1] Univ Klinikum Wurzburg, Zentrum Innere Med, Med Klin & Poliklin 2, Rheumatol Klin Immunol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany

[2] Univ Klinikum Wurzburg, Frauenklin & Poliklin, Wurzburg, Germany

[3] Kathol Klinikum Mainz, Klin Frauenheilkunde & Geburtshilfe, Mainz, Germany

来源：

ZEITSCHRIFT FUR RHEUMATOLOGIE | 2016年 / 75卷 / 01期

关键词：

Immunosuppression; Breast cancer; Ovarian cancer; Cervical cancer; Systemic lupus erythematosus; BREAST-CANCER; FOLLOW-UP; INTRAEPITHELIAL NEOPLASIA; THERAPY; RISK; ARTHRITIS; WOMEN; METAANALYSIS; DIAGNOSIS; SURVIVAL;

D O I：

10.1007/s00393-016-0044-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The risk of gynecological cancers in patients with inflammatory rheumatic diseases only seems to be elevated with respect to cervical cancer and mainly in patients with systemic lupus erythematosus. There is increasing evidence for an influence of the immune system on tumor control of gynecological malignancies; however, an adverse influence of immunosuppressive treatment in rheumatic patients was indicated only for the risk of cervical cancer. In contrast, biologics could not be shown to cause an increased risk of cervical cancer but data on this topic are limited. General screening recommendations exist for breast cancer and cervical cancer. Recommendations for follow-up after oncological treatment are presented. Because of limited evidence immunosuppressive and biological treatment should be applied with great restraint at least within the first 5 years after curative oncological treatment also for gynecological tumors. As far as breast cancer is concerned an even longer interval is under discussion.

引用

页码：63 / 67

页数：5

共 32 条

[1]

[Anonymous], 2013, S3 LEITLINIE DIAGNOS

[2]

[Anonymous], S3 LEITLINIE MAMMAKA

[3]

[Anonymous], PRAVENTION DIAGNOSTI

[4]

[Anonymous], 2010, Diagnostik und Therapie primarer und metastasierter Mammakarzinome

[5] Malignant progression of precancerous lesions of the uterine cervix following biological DMARD therapy in patients with arthritis [J].

Cordtz, Rene ;

Mellemkjaer, Lene ;

Glintborg, Bente ;

Hetland, Merete Lund ;

Dreyer, Lene .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (07) :1479-U206

[6]

Dugué PA, 2013, EXPERT REV ANTICANC, V13, P29, DOI [10.1586/era.12.159, 10.1586/ERA.12.159]

[7]

Emens LA, 2012, EXPERT REV ANTICANC, V12, P1597, DOI [10.1586/ERA.12.147, 10.1586/era.12.147]

[8]

Empfehlungen der Standigen Impfkommission (STIKO) am Robert Koch-Institut, 2014, EPIDEMIOLOGISCHES B, V25

[9]

Griesser, 2014, FRAUENARZT, V54, P1042

[10] Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update) [J].

Grunfeld, E ;

Dhesy-Thind, S ;

Levine, M .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (10) :1319-1320

← 1 2 3 4 →